Core Viewpoint - The acquisition of a 49% stake in Optimed Holding GmbH by the company marks a significant milestone in its long-term commitment to global expansion and aims to enhance its competitive position in the international market [1][2]. Group 1: Acquisition Details - The company has entered into a purchase agreement to acquire 49% of Optimed Holding GmbH for approximately €18.375 million [1]. - The agreement includes an option for the company to acquire the remaining shares from other shareholders at its discretion [1]. - Post-acquisition, Optimed will not become a subsidiary of the company, and its financial performance will not be consolidated into the company's financial statements [1]. Group 2: Strategic Benefits - The acquisition is a key milestone for the company's entry into the European and global markets, facilitating asset integration to accelerate international strategy deployment and diversify the product portfolio [2]. - The integration with Optimed's sales network will enhance the global application of innovative vascular solutions, leveraging strong relationships with European medical experts to expedite clinical processes and product launches [2]. - The transaction is expected to create significant manufacturing and operational synergies between Germany and China, improving product quality and operational efficiency while expanding production capacity in Germany [2]. Group 3: R&D and Commercialization - The integrated global commercialization platform will fully leverage the company's R&D capabilities, aiming to provide cutting-edge medical solutions to patients and healthcare professionals worldwide [3]. - Following the acquisition, the company and Optimed will integrate their commercialization platforms, including sales and marketing networks, enhancing international sales capabilities [3]. - Optimed will serve as the exclusive distributor for all vascular products in markets outside mainland China, with Rüdiger Hausherr continuing as CEO of Optimed [3].
归创通桥拟1837.5万欧元收购Optimed Holding 49%股权 为进军欧洲及全球市场的关键里程碑